Join Cue Biopharma (CUE) for a virtual event featuring two key opinion leaders (KOLs) Richard DiPaolo, PhD (Saint Louis University) and Andrew Cope, MD, PhD (Centre for Rheumatic Diseases, King’s College London). Together with Cue’s management, they will discuss Cue’s disruptive and highly differentiated biologics platform, which has the unique potential to selectively activate and expand disease relevant T cells, with reduced risk of adverse events.

The event will feature a review of the CUE-400 series, including new preclinical proof-of-concept data for lead candidate, CUE-401, aimed at transforming the standard of care for autoimmune diseases and inflammation. Cue will also provide an overview of the CUE-500 program, including CUE-501, recently partnered with Boehringer Ingelheim, leveraging anti-viral killer T cells for autoimmune diseases and cancer. The Company will also provide key updates on the CUE-100 series clinical oncology programs.

A live question and answer session will follow the formal presentations.